Mind Medicine (MindMed) (MNMD) Stock Price, News & Analysis

Company Overview

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $9.68 to $9.85
• 50-Day Range: $6.49 to $10.19
• 52-Week Range: $4.70 to $11.02
• Volume: 75,416 shs
• Average Volume: 1.49 million shs
• Market Capitalization: $704.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.71
• Consensus Rating: Buy

Mind Medicine (MindMed) Stock Analysis - MarketRank™

Mind Medicine (MindMed) scored higher than 54% of companies evaluated by MarketBeat, and ranked 519th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mind Medicine (MindMed) has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mind Medicine (MindMed) are expected to grow in the coming year, from ($1.35) to ($0.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mind Medicine (MindMed) is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mind Medicine (MindMed) is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mind Medicine (MindMed) has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.37% of the float of Mind Medicine (MindMed) has been sold short.

Short Interest Ratio / Days to Cover

Mind Medicine (MindMed) has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Mind Medicine (MindMed) has recently decreased by 6.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mind Medicine (MindMed) does not currently pay a dividend.

Dividend Growth

Mind Medicine (MindMed) does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.37% of the float of Mind Medicine (MindMed) has been sold short.

Short Interest Ratio / Days to Cover

Mind Medicine (MindMed) has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Mind Medicine (MindMed) has recently decreased by 6.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.05

News Sentiment

Mind Medicine (MindMed) has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Mind Medicine (MindMed) this week, compared to 3 articles on an average week.

Search Interest

19 people have searched for MNMD on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.

MarketBeat Follows

Only 10 people have added Mind Medicine (MindMed) to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mind Medicine (MindMed) insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $311,644.00 in company stock.

Percentage Held by Insiders

Only 2.45% of the stock of Mind Medicine (MindMed) is held by insiders.

Percentage Held by Institutions

Only 27.91% of the stock of Mind Medicine (MindMed) is held by institutions.

MNMD Stock Analysis - Frequently Asked Questions

How have MNMD shares performed this year?

Mind Medicine (MindMed)'s stock was trading at $6.96 on January 1st, 2025. Since then, MNMD shares have increased by 40.5% and is now trading at $9.78.

How were Mind Medicine (MindMed)'s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) released its earnings results on Thursday, July, 31st. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.12.
Read the conference call transcript.

When did Mind Medicine (MindMed)'s stock split?

Shares of Mind Medicine (MindMed) reverse split on Monday, August 29th 2022.The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Mind Medicine (MindMed)'s major shareholders?

Top institutional investors of Mind Medicine (MindMed) include Commodore Capital LP (6.57%), Marshall Wace LLP (4.50%), Octagon Capital Advisors LP (2.80%) and Geode Capital Management LLC (2.29%). Insiders that own company stock include Robert Barrow, Daniel Karlin, Dan Karlin, Mark Sullivan, Schond L Greenway, Carrie Liao and David W Gryska.
View institutional ownership trends.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mind Medicine (MindMed) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mind Medicine (MindMed) investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Tesla (TSLA) and

Company Calendar

• Last Earnings: 7/31/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNMD
• CIK: 1813814
• Web: www.mindmed.co
• Phone: 650-208-2454
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Mind Medicine (MindMed): $24.71
• High Price Target: $55.00
• Low Price Target: $14.00
• Potential Upside/Downside: +152.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$108.68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.24%
• Return on Assets: -39.41%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 4.98
• Quick Ratio: 4.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.44 per share
• Price / Book: 4.01

Miscellaneous

• Outstanding Shares: 76,090,000
• Free Float: 74,224,000
• Market Cap: $744.16 million
• Optionable: Optionable
• Beta: 2.49